Pre-clinical and early phase clinical studies with remote ischemic preconditioning (RIPC) appeared promising; however, RIPC was not effective in phase III clinical trials. To improve the translation of RIPC into clinical practice, the kinetic properties and functional effects of humoral factors released after RIPC in humans were characterized ex vivo. Venous blood from 20 healthy volunteers was collected at baseline and 5 min, 30 min, 1 h, 6 h and daily from 1 to 7 days after RIPC. Plasma dialysates were infused into Langendorff-perfused mouse hearts subjected to 20/120 min global ischemia/reperfusion. Perfusion with dialysates obtained 5 min to 6 days after RIPC significantly reduced infarct size by w50% when compared to perfusion with dialysates obtained at baseline prior to RIPC, and increased STAT3 phosphorylation beyond values obtained with baseline-dialysate.
SUMMARY
Although remote ischemic pre-conditioning (RIPC) reduced infarct size in animal experiments and proof-of-concept clinical trials, recent phase III trials failed to confirm cardioprotection during cardiac surgery. Here, we characterized the kinetic properties of humoral factors that are released after RIPC, as well as the signal transduction pathways that were responsible for cardioprotection in an ex vivo model of global ischemia reperfusion injury. Venous blood from 20 healthy volunteers was collected at baseline and 5 min, 30 min, 1 h, 6 h, and daily from 1 to 7 days after RIPC (3 Â 5/5 min upper-limb ischemia/reperfusion). Plasma-dialysates (cut-off: 12 to 14 kDa; dilution: 1:20) were infused into Langendorff-perfused mouse hearts subjected to 20/120 min global ischemia/reperfusion. Infarct size and phosphorylation of signal transducer and activator of transcription (STAT)3, STAT5, extracellular-regulated kinase 1/2 and protein kinase B were determined. In a subgroup of plasma-dialysates, an inhibitor of STAT3 (Stattic) was used in mouse hearts.
Perfusion with baseline-dialysate resulted in an infarct size of 39% of ventricular mass (interquartile range: 36% to 42%). Perfusion with dialysates obtained 5 min to 6 days after RIPC significantly reduced infarct size by w50% and increased STAT3 phosphorylation beyond that with baseline-dialysate. Inhibition of STAT3 abrogated these effects.
These results suggest that RIPC induces the release of cardioprotective, dialyzable factor(s) within 5 min, and that circulate for up to 6 days. STAT3 is activated in murine myocardium by RIPC-induced human humoral factors and is RIC has been demonstrated in many experimental studies and also attenuates myocardial ischemia/ reperfusion injury in patients undergoing elective interventional (2) or surgical coronary revascularization (3-5) as well as in patients with acute myocardial infarction (6) (7) (8) (9) (10) . The efficacy of RIC was evidenced by reduced cardiac biomarker release (2- 5, 9) and reduced infarct size on magnetic resonance imaging (6, 8, 10) ; some smaller studies also reported improved short- (5, 8) (11, 12) . Reasons for the failure of these trials to confirm protection by RIPC have been discussed in detail and related to confounding variables (13-15), notably the use of propofol in the majority of all patients in both trials, which might have abrogated the cardioprotective effect (16) .
For more successful translation of experimental animal studies and smaller proof-of-concept trials to clinical reality a better understanding of RIC's signal transduction is mandatory. In particular, the transfer signal from the remote peripheral organ where the RIC maneuver is performed to the heart is still enigmatic. Both neuronal and humoral transfer as well as a neurohumoral interaction have been proposed.
Humoral transfer by nitrite (17) , stromal cell-derived factor-1a (18) , and microRNA-144 (19) has been reported. More systematic proteome analyses of plasma taken after RIPC have not yet identified a specific protein (20, 21) .
We therefore used another strategy to identify the potential humoral transfer factor(s) by characterizing their properties in kinetic terms and by the signal activation which they elicit in the heart to effect cardioprotection. Prior studies have reported a time delay between the RIPC stimulus and the injurious event from 5 to 10 min (22, 23) to more than 24 h (24) (25) (26) (27) , suggesting that RIPC is a fast acting as well as a long-lasting phenomenon. Supporting the notion of a long-lasting effect, flow-mediated forearm vasodilation in patients with reperfused acute myocardial infarction was improved by RIPC for 1 week (28) .
However, this particular study could not distinguish whether there was a long-lasting circulation of transfer factor(s) or a long-lasting effect in the target organ. We have therefore obtained plasma from healthy volunteers at different time points before and after a RIPC maneuver and tested its cardioprotective effect in a Langendorff-perfused mouse heart used as bioassay. Cardioprotection relies on a complex signal transduction of triggers, mediators, and effectors, which also vary between different species (29) . The cytosolic signal transduction within the cardiomyocyte includes the reperfusion injury salvage kinase (SAFE) and the survival activating factor enhancement systems (30) , and both these systems are also recruited for cardioprotection in mice (31) (32) (33) (34) .
We therefore went on to identify the signal transduction, which was activated by the transfer of a human plasma-dialysate to achieve infarct size reduction in the bioassay mouse heart. Plasma from 20 volunteers was obtained at 12 pre-defined time points and dialyzed with a dilution of 1:20 for 24 h, using a cutoff of 12 to 14 kDa. After 20 min of stabilization, isolated mouse hearts were perfused with dialysates of human plasma for 15 min, followed by 5 min of wash-out by perfusion with Krebs-Henseleit buffer, before undergoing 20 min of global ischemia. After 120 min of reperfusion, infarct size was determined with 2,3,5-triphenyltetrazolium chloride (TTC) staining, and activation of proteins was analyzed with Western blot analysis. KINETICS OF HUMORAL FACTOR(S). The release of a circulating factor with a rapid onset of cardioprotection in the bioassay heart of the present study is consistent with prior experimental and clinical studies, which revealed evidence for protection with an interval of only 5 to 10 min between the RIPC stimulus and the injurious event (22, 23, 37, 38) .
RESULTS

Volunteer
The continuous presence of a circulating factor that provides cardioprotection in the bioassay mouse heart in the present study is again consistent with prior experimental and clinical studies, which revealed evidence of long-lasting protection (24, 26, 27, 39) for up to 1 week after the RIPC stimulus (28) . In contrast to our present study, however, these studies could not distinguish between a long-lasting presence of a circulating factor or a long-lasting protective effect in the target organ. Given the dilution of the circulating factor that we had to use for technical reasons to perfuse the mouse heart with a dialysate, the appearance of a circulating factor which initiates protection may even be faster and last longer than we observed. However, we cannot distinguish whether we are dealing with the rapid and continuous release of a factor with a short half-life or a rapid release of a factor with a long half-life. Also, we have no information whether we In the present study, we have not investigated potential candidate molecules-nitrite (17) founding co-morbidities and comedications. Also, the signal transduction and the protective effect may be quantitatively and qualitatively different in the diseased human than the healthy mouse heart (13) .
CONCLUSIONS
A single RIPC maneuver in healthy volunteers induces release of 1 or more cardioprotective, dialyzable, humoral factors that circulate already after 5 min and for up to 6 days. These factors reduce infarct size through STAT3 activation in the mouse heart.
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